Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             147 results found
no title author magazine year volume issue page(s) type
1 CA2: COST COMPARISONS BETWEEN HOSPITALS IN DIFFERENT COUNTRIES BY MEANS OF A RESOURCE USE INDEX Neymark, N
 1999
 2 5 p. 360-
1 p.
 article
2 CA3: ESTIMATING SURVIVAL GAIN FOR COST-EFFECTIVENESS ANALYSIS: THE EXAMPLE OF EARLY HORMONAL TREATMENT IN LOCALLY ADVANCED PROSTATE CANCER Neymark, N
 1999
 2 5 p. 360-361
2 p.
 article
3 CA4: METASTATIC BREAST CANCER PATIENTS TREATED WITH DOCETAXEL Burrell, A
 1999
 2 5 p. 361-
1 p.
 article
4 CA1: PROSPECTIVE ECONOMIC EVALUATION OF ANTIBIOTIC PROPHYLAXIS IN SMALL CELL LUNG CANCER (SCLC) PATIENTS RECEIVING CHEMO THERAPY Caleo, S
 1999
 2 5 p. 359-360
2 p.
 article
5 CA5: QUALITY OF LIFE IN A BREAST CANCER POPULATION UNDERGOING ADJUVANT TREATMENT Nichol, MB
 1999
 2 5 p. 361-
1 p.
 article
6 CN2: AN ECONOMIC COMPARISON OF OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE Gregor, KJ
 1999
 2 5 p. 353-354
2 p.
 article
7 CN3: COST-EFFECTIVENESS OF RT-PA IN TREATMENT OF ACUTE ISCHAEMIC STROKE IN UK Chambers, M
 1999
 2 5 p. 354-
1 p.
 article
8 CN1: COSTS OF DEMENTIA IN GERMANY—AN ANALYSIS OF 7490 HEALTH INSURANCE FILES Schwarz, UI
 1999
 2 5 p. 353-
1 p.
 article
9 CN4: ECONOMIC APPROACH FOR ASSESSING THE OVERALL COST OF MANAGING ISCHEMIC EVENTS (MYOCARDIAL INFARCTION STROKE) IN ATHEROTHROMBOTIC PATIENTS: A EUROPEAN OVERVIEW Levy, E
 1999
 2 5 p. 354-355
2 p.
 article
10 CN6: EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT OF HYPERTENSION UNDER EVERYDAY CIRCUMSTANCES WITH REGARD TO THE REDUCTION OF STROKE INCIDENCE Klungel, OH
 1999
 2 5 p. 355-356
2 p.
 article
11 CN8: PRODUCTIVITY COST MEASUREMENT: EMPIRICAL ANALYSIS OF QALY, HUMAN CAPITAL AND FRICTION COST METHODOLOGIES Rothermich, EA
 1999
 2 5 p. 356-
1 p.
 article
12 CN7: REDUCING ANTICHOLINERGIC ANTIDEPRESSANT USE IN THE ELDERLY: A RANDOMIZED TRIAL OF GROUP VERSUS INDIVIDUAL “ACADEMIC DETAILING” Van, Eijk MEC
 1999
 2 5 p. 356-
1 p.
 article
13 CN5: THE COST OF INPATIENT TREATMENT OF SCHIZOPHRENIA: A STUDY OF TWO LEADING ATYPICAL ANTIPSYCHOTICS Duchesne, I
 1999
 2 5 p. 355-
1 p.
 article
14 Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe Drummond, Michael
 1999
 2 5 p. 323-332
10 p.
 article
15 CV3: A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL AS TREATMENT FOR HYPERTENSION IN THE UNITED STATES Doyle, J
 1999
 2 5 p. 351-
1 p.
 article
16 CV7: AMLODIPINE REDUCES HOSPITALIZATION ASSOCIATED WITH TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH CLINICAL CORONARY ARTERY DISEASE Chen, G
 1999
 2 5 p. 352-353
2 p.
 article
17 CV2: AN ECONOMIC ASSESSMENT OF DALTEPARIN VERSUS WARFARIN IN TOTAL HIP REPLACEMENT Pleil, A
 1999
 2 5 p. 350-351
2 p.
 article
18 CV6: COST-EFFECTIVENESS OF STATINS: MOVING BEYOND THE PRIMARY AND SECONDARY PREVENTION DISTINCTION Caro, J
 1999
 2 5 p. 352-
1 p.
 article
19 CV8: DETERMINANTS OF DISCONTINUATION OF NEW COURSES OF ANTIHYPERTENSIVE MEDICATIONS Gregoire, JP
 1999
 2 5 p. 353-
1 p.
 article
20 CV1: LONG TERM COMPLIANCE WITH ANTIHYPERTENSIVE DRUG THERAPY IN A MANAGED CARE ORGANIZATION Simons, R
 1999
 2 5 p. 350-
1 p.
 article
21 CV5: SIMULATED LIFETIME COSTS TO NATIONAL HEALTH SERVICE (NHS) OF BIOLOGICAL AND MECHANICAL HEART VALVE REPLACEMENT IN YOUNGER VERSUS OLDER PATIENTS Griffiths, R
 1999
 2 5 p. 351-352
2 p.
 article
22 CV4: THE COST OF HYPERTENSION AND ITS CORRELATES IN EMILIA ROMAGNA REGION (ITALY): RESULTS FROM THE GREAT STUDY Ambrosioni, E
 1999
 2 5 p. 351-
1 p.
 article
23 ED2: COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS Wilson, LS
 1999
 2 5 p. 369-
1 p.
 article
24 ED1: COST-EFFECTIVENESS OF INTENSIVE METFORMIN VERSUS CONVENTIONAL THERAPY FOR OBESE PATIENTS WITH TYPE 2 DIABETES Palmer, AJ
 1999
 2 5 p. 369-
1 p.
 article
25 ED3: DEALING WITH CO-MORBIDITY AND RARE COMPLICATIONS IN A DIABETES TYPE 2 COST OF ILLNESS STUDY Spannheimer, A
 1999
 2 5 p. 370-
1 p.
 article
26 ED4: QUALITY OF LIFE AND USE OF HEALTHCARE RESOURCES IN GROWTH HORMONE-DEFICIENT ADULTS AFTER GROWTH HORMONE REPLACEMENT THERAPY Hernberg-Ståhl, E
 1999
 2 5 p. 370-
1 p.
 article
27 GI2: COST-EFFECTIVENESS ANALYSIS OF HIGH DOSE IV OMEPRAZOLE INFUSION AS ADJUVANT THERAPY TO ENDOSCOPIC HAEMOSTASIS FOR BLEEDING PEPTIC ULCERS Lee, KKC
 1999
 2 5 p. 366-
1 p.
 article
28 GI1: COST-EFFECTIVENESS OF THE COMBINATION OF MISOPROSTOL WITH DICLOFENAC IN THE TAYSIDE POPULATION Morant, S
 1999
 2 5 p. 365-366
2 p.
 article
29 GI3: EVALUATION OF PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: COSTS SAVINGS AND CLINICAL EFFECTS Cousin, C
 1999
 2 5 p. 366-367
2 p.
 article
30 GI4: PREDICTORS OF SAMPLE INCLUSION FOLLOWING THE APPLICATION OF CONTINUOUS ELIGIBILITY REQUIREMENTS IN SUBJECTS RECEIVING COLONOSCOPIES Bramley, T
 1999
 2 5 p. 367-
1 p.
 article
31 IR7: A SYSTEMATIC REVIEW OF SYSTEMIC AND TOPICAL ANTIMICROBIAL AGENTS USED IN THE PREVENTION AND TREATMENT OF CHRONIC WOUNDS O'Meara, S
 1999
 2 5 p. 359-
1 p.
 article
32 IR4: BUDESONIDE GAVE LOWER HEALTH CARE COSTS IN ASTHMA TREATMENT THAN FLUTICASONE PROPIONATE Ericsson, Å
 1999
 2 5 p. 357-358
2 p.
 article
33 IR8: COST-EFFECTIVENESS OF COMBINED HEPATITIS A AND B VACCINATION AND HEPATITIS B MONOVACCINATION IN SWITZERLAND AND AUSTRIA Schneller, P
 1999
 2 5 p. 359-
1 p.
 article
34 IR3: COST OF NOSOCOMIAL PNEUMONIA IN A LARGE TEACHING HOSPITAL Dietrich, ES
 1999
 2 5 p. 357-
1 p.
 article
35 IR5: DECISION ANALYSIS OF ACUTE TONSILLOPHARYNGITIS MANAGEMENT IN RUSSIAN CHILDREN Stratchounski, L
 1999
 2 5 p. 358-
1 p.
 article
36 IR6: DEVELOPMENT AND PRELIMINARY RESULTS OF THE HEALTH AND ECONOMIC CONSEQUENCES OF SMOKING MODEL Orme, M
 1999
 2 5 p. 358-359
2 p.
 article
37 IR2: THE COSTS OF THE INADEQUATE USE OF ANTIBIOTICS Rovira, J
 1999
 2 5 p. 357-
1 p.
 article
38 IR1: THE HEALTH ECONOMICS OF RECLASSIFICATION OF DRUGS FROM PRESCRIPTION ONLY MEDICINES TO PHARMACY STATUS Rowlands, S
 1999
 2 5 p. 356-357
2 p.
 article
39 PCA6: COST OF POSTMENOPAUSAL BREAST CANCER IN BELGIUM: AN INCIDENCE BASED APPROACH Annemans, L
 1999
 2 5 p. 384-
1 p.
 article
40 PCA5: EVALUATION OF POTENTIAL DRUG-INDUCED CHANGES IN HEALTH CARE UTILIZATION AND ATTENDANT COSTS: MODELS, DATABASE, AND EXAMPLES Farquhar, I
 1999
 2 5 p. 383-
1 p.
 article
41 PCA2: IRINOTECAN IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: IMPROVED SURVIVAL AND COST EFFECTIVENESS COMPARED WITH INFUSIONAL 5-FLUOROURACIL Jackson, DL
 1999
 2 5 p. 382-
1 p.
 article
42 PCA1: PHARMACOECONOMIC EVALUATION OF FILGRASTIM (r-metHuG-CSF) TREATMENT IN AUTOLOGOUS BONE MARROW TRANSPLANTATION Privitera, G
 1999
 2 5 p. 382-
1 p.
 article
43 PCA4: TRANSLATION OF THE QOL-RTI H&N QUESTIONNAIRE FOR ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS UNDERGOING RADIATION THERAPY FOR HEAD AND NECK CANCER Johnson, DJ
 1999
 2 5 p. 383-
1 p.
 article
44 PCA3: TREATMENT PATHWAYS, RESOURCE USE AND COSTS IN THE MANAGEMENT OF SMALL CELL LUNG CANCER Oliver, E
 1999
 2 5 p. 382-383
2 p.
 article
45 PCN4: A COMPARISON OF ADULT MIGRAINE TREATMENT REGIMENS IN A MANAGED CARE POPULATION Eaddy, M
 1999
 2 5 p. 385-
1 p.
 article
46 PCN10: A CROSS-SECTIONAL ANALYSIS OF HEALTH CARE COST OF SSRI USERS Goodman, M
 1999
 2 5 p. 387-388
2 p.
 article
47 PCN8: ANTIPSYCHOTIC DRUG USE AND HOSPITALISATION IN PATIENTS WITH SCHIZOPHRENIA de Vries, CS
 1999
 2 5 p. 387-
1 p.
 article
48 PCN3: COST ANALYSIS OF SCHIZOPHRENIA TREATMENT IN GERMANY: A COMPARISON OF OLANZAPINE, RISPERIDONE, AND HALOPERIDOL USING A CLINICAL DECISION MODEL Spannheimer, A
 1999
 2 5 p. 385-
1 p.
 article
49 PCN9: COST-EFFECTIVENESS ANALYSIS AND SOCIAL ASPECTS OF THE PALMITATE PIPOTIASINE OUTPATIENT TREATMENT IN SCHIZOPHRENIA Gurovich, I
 1999
 2 5 p. 387-
1 p.
 article
50 PCN1: DIRECT AND INDIRECT TREATMENT COMPARISONS OF SECOND-GENERATION ANTIPSYCHOTIC DRUGS Sauriol, L
 1999
 2 5 p. 384-
1 p.
 article
51 PCN2: DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE: RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO) Sacristán, JA
 1999
 2 5 p. 384-385
2 p.
 article
52 PCN7: ECONOMIC ASPECTS OF AN INTERNATIONAL STUDY OF MAJOR DEPRESSIVE DISORDER IN PRIMARY CARE PATIENTS (THE LIDO STUDY) Chisholm, D
 1999
 2 5 p. 386-
1 p.
 article
53 PCN12: HEALTH ECONOMICS FOR N-OF-1 TRIALS Qizilbash, N
 1999
 2 5 p. 388-
1 p.
 article
54 PCN6: MODELLING THE LONG-TERM COST EFFECTIVENESS OF RILUZOLE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Tavakoli, M
 1999
 2 5 p. 386-
1 p.
 article
55 PCN5: THE USE OF INTERNATIONAL, DISEASE SPECIFIC, CROSS-SECTIONAL DATABASES FOR PHARMACOECONOMIC RESEARCH Crawford, B
 1999
 2 5 p. 385-386
2 p.
 article
56 PCN11: UK SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (UK-SCAP)—A PROSPECTIVE, OBSERVATIONAL STUDY OF THE TREATMENT AND OUTCOMES OF DRUG THERAPY FOR SCHZOPHRENIA IN A NATURALISTIC SETTING McKendrick, J
 1999
 2 5 p. 388-
1 p.
 article
57 PCV7: AN ECONOMIC ANALYSIS OF TELMISARTAN (MICARDIS®) TREATMENT FOR PEOPLE WITH MILD TO MODERATE HYPERTENSION IN THE UK Backhouse, M
 1999
 2 5 p. 391-
1 p.
 article
58 PCV4: COST ANALYSIS OF AMLODIPINE VERSUS FELODIPINE ER IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION Berliner, E
 1999
 2 5 p. 390-
1 p.
 article
59 PCV9: COST-COMPARISON ANALYSIS OF HOME MONITORING AND AMBULANT MONITORING OF ORAL ANTICOAGULATION IN SWITZERLAND Neeser, K
 1999
 2 5 p. 392-
1 p.
 article
60 PCV6: COST OF SECOND LINE PHARMACEUTICAL MANAGEMENT OF ATRIAL FIBRILLATION IN FRANCE Annemans, L
 1999
 2 5 p. 391-
1 p.
 article
61 PCV3: COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER IN THE UNITED STATES Bhattacharyya, SK
 1999
 2 5 p. 389-390
2 p.
 article
62 PCV1: DIRECT COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS: A MODELING APPROACH Bhattacharyya, SK
 1999
 2 5 p. 388-389
2 p.
 article
63 PCV12: ECONOMIC EVALUATION OF ACE INHIBITORS IN SPAIN Asensio, J
 1999
 2 5 p. 393-
1 p.
 article
64 PCV8: HOSPITALIZATION PROFILE OF PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER: AN ADMINISTRATIVE DATABASE ANALYSIS Bhattacharyya, SK
 1999
 2 5 p. 391-392
2 p.
 article
65 PCV5: MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD) PATIENTS: MODELLING THE RISK OF ISCHEMIC EVENTS AND THEIR ECONOMIC CONSEQUENCES Levy, E
 1999
 2 5 p. 390-391
2 p.
 article
66 PCV10: PREDICTORS OF ADHERENCE TO LIPID-LOWERING THERAPY de Vries, CS
 1999
 2 5 p. 392-393
2 p.
 article
67 PCV11: STUDY OF HEALTH CARE RESOURCE USE FOR ELDERLY PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION Geltzer, B
 1999
 2 5 p. 393-
1 p.
 article
68 PCV2: THE COST-EFFECTIVENESS OF CHOLESTEROL LOWERING TREATMENT IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE: THE CASE OF A COMPREHENSIVE DIETARY INTERVENTION PROGRAM Long, K
 1999
 2 5 p. 389-
1 p.
 article
69 PEN8: CODE-2* UK: THE CURRENT COSTS OF TYPE-2 DIABETES IN THE UK Bottomley, J
 1999
 2 5 p. 396-
1 p.
 article
70 PEN6: COSTS OF TREATING NAIVE PATIENTS WITH TYPE 2 DIABETES—A COMPARISON BETWEEN THE UNITED KINGDOM AND FRANCE Pashos, CL
 1999
 2 5 p. 395-396
2 p.
 article
71 PEN3: DEVELOPMENT OF AN ALGORITHM FOR ESTIMATING ASTHMA SEVERITY FROM AN ADMINISTRATIVE COST DATABASE Leidy, NK
 1999
 2 5 p. 394-395
2 p.
 article
72 PEN7: DIRECT COSTS OF DIABETES IN ITALY Garattini, L
 1999
 2 5 p. 396-
1 p.
 article
73 PEN4: MEASURING THE REAL ANNUAL DIRECT COSTS OF DIABETES TYPE 2 PATIENTS IN GERMANY Goertz, A
 1999
 2 5 p. 395-
1 p.
 article
74 PEN5: METHODOLOGICAL ASPECTS OF MULTI-COUNTRY COST OF ILLNESS STUDIES—1: DATA COLLECTION INSTRUMENT DESIGN Kirsch, J
 1999
 2 5 p. 395-
1 p.
 article
75 PEN2: METHODOLOGICAL ASPECTS OF MULTI COUNTRY COST OF ILLNESS STUDIES—2: INTERNET BASED DATA MANAGEMENT Kirsch, J
 1999
 2 5 p. 394-
1 p.
 article
76 PEN9: PHARMACODYNAMIC-PHARMACOECONOMIC (PD-PE) MODEL OF ASTHMA ANTI-INFLAMMATORY THERAPIES Handley, DA
 1999
 2 5 p. 396-397
2 p.
 article
77 PEN1: QUALITY-OF-LIFE-EVALUATION OF THE GERMAN S.A.T.-TRIAL - COMPARISON OF SF-36, EUROQOL, TIME-TRADE-OFF METHOD AND WILLINGNESS-TO-PAY Wendland, G
 1999
 2 5 p. 393-394
2 p.
 article
78 PG15: COST OF ILLNESS STUDIES MAY LARGELY UNDERESTIMATE THE COST OF DISEASES WITH UNMET MEDICAL NEED SUCH AS IRRITABLE BOWEL SYNDROME (IBS) Volmer, T
 1999
 2 5 p. 399-
1 p.
 article
79 PG14: COST OF ITALIAN DYSPEPTIC PATIENTS: A FEASIBILITY STUDY FROM THE DYSPEPSIA PROJECT Triossi, O
 1999
 2 5 p. 398-
1 p.
 article
80 PG12: DIAGNOSIS AND TREATMENT OF CONSTIPATION IN A MANAGED CARE POPULATION Bramley, T
 1999
 2 5 p. 397-398
2 p.
 article
81 PG13: DIFFERENTIAL COST OF USING NSAIDS IN A MEDICAID POPULATION Dickson, WM
 1999
 2 5 p. 398-
1 p.
 article
82 PGI1: EFFECTIVENESS OF OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN IN ERADICATING HELICOBACTER PYLORI IN PATIENTS ON CHRONIC ACID SUPPRESSION FOR PEPTIC ULCER DISEASE OR ULCER-LIKE SYMPTOMS Allison, J
 1999
 2 5 p. 397-
1 p.
 article
83 Pharmacoeconomics in European Decision-Making Nuijten, Mark JC
 1999
 2 5 p. 319-322
4 p.
 article
84 PID2: ASSESSING THE DIRECT COST OF LYME DISEASE Goodman, M
 1999
 2 5 p. 401-
1 p.
 article
85 PID4: COST-EFFECTIVENESS OF PARTNER PHARMACOTHERAPY IN SCREENING FOR CHLAMYDIA TRACHOMATIS Postma, MJ
 1999
 2 5 p. 402-
1 p.
 article
86 PID1: ESTIMATES OF THE INDIRECT COSTS OF HIV AND AIDS IN THE UNITED KINGDOM Mullins, CD
 1999
 2 5 p. 401-
1 p.
 article
87 PID3: HOSPITALIZATION RATES AND ASSOCIATED COSTS FOR INFLUENZA IN A MANAGED CARE POPULATION Eaddy, M
 1999
 2 5 p. 401-402
2 p.
 article
88 PID5: RETROSPECTIVE STUDY COMPARING COST-EFFECTIVENESS OF NEWER AMPHOTERICIN B PREPARATIONS Tsakalou, A
 1999
 2 5 p. 402-403
2 p.
 article
89 PID6: TREATMENT OF ACUTE OTITIS MEDIA IN A MANAGED CARE POPULATION McLaughlin, T
 1999
 2 5 p. 403-
1 p.
 article
90 PMW4: A MICRO-COST ANALYSIS OF URINARY INCONTINENCE CARE IN LONG-TERM CARE FACILITIES Hartzema, AG
 1999
 2 5 p. 400-401
2 p.
 article
91 PMW1: COSTS OF TREATMENT WITH DOXAZOSIN VERSUS TAMSULOSIN IN MEN WITH BENIGN PROSTATIC HYPERPLASIA Thompson, D
 1999
 2 5 p. 399-
1 p.
 article
92 PMW3: ECONOMICAL ANALYSIS OF THE RESULTS OF PROSTATE CANCER SCREENING PROGRAM Komarova, LE
 1999
 2 5 p. 400-
1 p.
 article
93 PMW2: THE VALUATION OF ERECTILE DYSFUNCTION: CONVERTING CLINICAL OUTCOMES INTO UTILITIES Stolk, EA
 1999
 2 5 p. 399-400
2 p.
 article
94 PTH5: A COST-MINIMIZATION ANALYSIS OF IRON DEFICIENCY ANEMIA TREATMENT Vorobiev, PA
 1999
 2 5 p. 405-
1 p.
 article
95 PTH11: APPLYING DECISIONAL ANALYSIS TO METERED DOSE INHALER MONITORING AND EDUCATIONAL OUTCOMES Sampson, JM
 1999
 2 5 p. 407-
1 p.
 article
96 PTH4: ECONOMIC EVALUATION BY UK PHARMACEUTICAL AND MEDICAL DEVICE FIRMS: GENERAL TRENDS AND POLICY IMPLICATIONS Cookson, R
 1999
 2 5 p. 404-405
2 p.
 article
97 PTH10: EVALUATING PHARMACEUTICAL COSTS OF PATIENTS WITH CHRONIC LUNG DISEASE IN GERMAN IN- AND OUTPATIENTS SETTING Hessel, F
 1999
 2 5 p. 407-
1 p.
 article
98 PTH7: GLOBAL SCALE VERSUS GENERIC AND DISEASE-SPECIFIC INSTRUMENTS TO MEASURE THE HEALTH STATUS OF PATIENTS WITH ASTHMA Hajiro, T
 1999
 2 5 p. 405-406
2 p.
 article
99 PTH3: GUIDELINES FOR SUBMISSION OF REQUESTS FOR INCLUSION OF A PHARMACEUTICAL PRODUCT IN THE ISRAELI NATIONAL FORMULARY Shani, S
 1999
 2 5 p. 404-
1 p.
 article
100 PTH12: INTENSIVE CARE COSTS OF TREATING PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME: HOW CAN THESE BE MEASURED? Sauriol, L
 1999
 2 5 p. 407-408
2 p.
 article
101 PTH2: MALIGNANT RETROPERITONEAL TUMOURS OF CHILDREN: FIRST RESEARCH OF QUALITY OF LIFE OF 278 SURVIVED PATIENTS Zaeva, G
 1999
 2 5 p. 403-404
2 p.
 article
102 PTH6: PATIENTS' PERCEPTIONS OF THE OUTCOMES OF TREATMENT WITH TOPICAL NSAIDS, RUBIFACIANTS AND ORAL PAIN REMEDIES. A PROSPECTIVE STUDY OF MEDICINES AVAILABLE THROUGH COMMUNITY PHARMACIES McNaughton, D
 1999
 2 5 p. 405-
1 p.
 article
103 PTH8: POTENTIAL COST SAVINGS ASSOCIATED WITH ASTHMA DRUG THERAPIES USING INTEGRATED DRUG AND MEDICAL CLAIMS DATA Andrews, K
 1999
 2 5 p. 406-
1 p.
 article
104 PTH9: RETROSPECTIVE OUTCOMES ANALYSIS OF THE EFFECTS OF ZAFIRLUKAST THERAPY IN THE MANAGEMENT OF PATIENTS WITH ASTHMA IN THE UNITED STATES Silverman, S
 1999
 2 5 p. 406-407
2 p.
 article
105 PTH13: THE APPLICATION OF PORTFOLIO MANAGEMENT TECHNIQUES TO PHARMACEUTICAL R&D PROJECT SELECTION AND COST-EFFECTIVENESS ANALYSIS Tran, G
 1999
 2 5 p. 408-
1 p.
 article
106 PTH1: USE OF ADMINISTRATIVE DATA FOR POST-MARKET SURVEILLANCE OF THE OUTCOME OF TOTAL HIP AND KNEE REPLACEMENTS Silverman, B
 1999
 2 5 p. 403-
1 p.
 article
107 QL3: ANTIPSYCHOTIC TREATMENT AND CHANGES IN HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA USING EQ-5D Badia, X
 1999
 2 5 p. 362-363
2 p.
 article
108 QL5: ASTHMA BOTHER PROFILE VERSUS AIRWAY QUESTIONNAIRE 20 AS SIMPLE MEASURES TO EVALUATE THE HEALTH STATUS IN ASTHMA Nishimura, K
 1999
 2 5 p. 363-
1 p.
 article
109 QL2: PSYCHOMETRIC EQUIVALENCE EVALUATION OF FIVE NON-WESTERN-LANGUAGE TRANSLATED VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY—GENERAL (FACT-G) VERSION 4 Eremenco, S
 1999
 2 5 p. 362-
1 p.
 article
110 QL1: THE QUALITY OF LIFE OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY: PREDICTORS AND RELEVANCE TO MANAGEMENT COMPLIANCE Golubev, SA
 1999
 2 5 p. 361-362
2 p.
 article
111 QL4: USING RASCH MODELS TO IMPROVE THE EVALUATIVE-SCALE PROPERTIES OF THE WOMEN'S HEALTH QUESTIONNAIRE Turner, R
 1999
 2 5 p. 363-
1 p.
 article
112 SD2: GENERICS ONLY OR GENERICS AND EFFICIENT DRUGS? Bendahan, G
 1999
 2 5 p. 368-
1 p.
 article
113 SD4: QUALITY OF LIFE ASSESSMENT AS A NEW OUTCOME MEASURE IN CLINICAL PRACTICE Pratheepawanit, N
 1999
 2 5 p. 368-369
2 p.
 article
114 SD1: USING CONJOINT ANALYSIS TO ASSESS WOMEN'S PREFERENCES FOR MATERNITY CARE SERVICES DURING THE INTRAPARTUM STAGE Ratcliffe, J
 1999
 2 5 p. 367-368
2 p.
 article
115 SD3: USING ECONOMIC INFORMATION IN HOSPITAL FORMULARY DECISION-MAKING Späth, HM
 1999
 2 5 p. 368-
1 p.
 article
116 SR2: A PHARMACO-ECONOMIC CASE STUDY IN ANAESTHESIA, INCLUDING A RECENT RE-ANALYSIS USING BOOTSTRAP TECHNIQUES McNamara, J
 1999
 2 5 p. 364-
1 p.
 article
117 SR3: DEVELOPMENT AND VALIDATION OF THE QUALITY OF LIFE WITH MIGRAINE (QOLWM): A BRIEF MIGRAINE SURVEY Cramer, JA
 1999
 2 5 p. 364-365
2 p.
 article
118 SR4: LONGITUDINAL ASSESSMENT OF ASTHMA AND WORK OUTCOMES Erickson, SR
 1999
 2 5 p. 365-
1 p.
 article
119 SR5: MEDICAL EVENTS AND RESOURCE UTILISATION IN CANCER PAIN PATIENTS TREATED WITH STRONG OPIOIDS: AN ANALYSIS OF THE UK-GPRD DATABASE Nuyts, GD
 1999
 2 5 p. 365-
1 p.
 article
120 SR1: THE ECONOMIC IMPACT OF TOLTERODINE IN PORTUGAL Dias, J
 1999
 2 5 p. 363-364
2 p.
 article
121 The Influence of Case Mix, Site Selection, and Methods Biases on Costs of Hospitalization For Acute Exacerbations of Chronic Obstructive Airways Disease and Lower Respiratory Tract Infections Davey, Peter G.
 1999
 2 5 p. 333-341
9 p.
 article
122 The Norwegian Version of the Psoriasis Disability Index — A Validation and Reliability Study Wahl, A.K.
 1999
 2 5 p. 342-349
8 p.
 article
123 TPC4: AN ECONOMIC EVALUATION OF AMLODIPINE FOR THE TREATMENT OF NONISCHEMIC DILATED CARDIOMYOPATHY: THE PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION (PRAISE) Glick, HA
 1999
 2 5 p. 379-380
2 p.
 article
124 TPC1: COST-EFFECTIVENESS ANALYSIS OF BUDESONIDE VERSUS DISODIUM CROMOGLYCATE THERAPY IN CHILDREN WITH MODERATE BRONCHIAL ASTHMA Szende, A
 1999
 2 5 p. 378-
1 p.
 article
125 TPC2: COST-MINIMIZATION ANALYSIS OF TWO TRIPLE REGIMENS FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED PEPTIC ULCER DISEASE You, JH
 1999
 2 5 p. 378-379
2 p.
 article
126 TPC3: COST OF AML TREATMENT IN BELGIUM: RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE Noens, L
 1999
 2 5 p. 379-
1 p.
 article
127 TPE1: ASSESSMENT OF THE APPROPRIATENESS OF CLINICAL GUIDELINES FOR CONTINUATION TREATMENT IN MAJOR DEPRESSION FROM A HEALTH ECONOMIC PERSPECTIVE Nuijten, MJC
 1999
 2 5 p. 374-
1 p.
 article
128 TPE5: COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM Annemans, L
 1999
 2 5 p. 376-
1 p.
 article
129 TPE4: DEVELOPMENT OF A QUALITY ASSESSMENT CHECKLIST FOR THE APPRAISAL OF ECONOMIC MODELS: A CASE-STUDY IN OSTEOPOROSIS Hege, U
 1999
 2 5 p. 375-376
2 p.
 article
130 TPE3: ECONOMIC EVALUATION OF DIFFERENT STRATEGIES OF A VACCINATION AGAINST HEPATITIS A AND HEPATITIS B Smala, A
 1999
 2 5 p. 375-
1 p.
 article
131 TPE2: ECONOMIC EVALUATION OF ENOXAPARIN AS POST DISCHARGE PROPHYLAXIS FOR DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE HIP SURGERY Davies, LM
 1999
 2 5 p. 375-
1 p.
 article
132 TPL3: BEST EVIDENCE IN PHARMACOECONOMICS Mallarkey, G
 1999
 2 5 p. 381-
1 p.
 article
133 TPL2: MULTINATIONAL ECONOMIC EVALUATIONS: A REVIEW OF PUBLISHED STUDIES, METHODOLOGICAL ISSUES AND PRACTICE Pang, F
 1999
 2 5 p. 380-
1 p.
 article
134 TPL1: STATE OF THE ART IN PHARMACOECONOMIC EVALUATION: A REVIEW OF METHODS AND PRACTICE Pang, F
 1999
 2 5 p. 380-
1 p.
 article
135 TPM5: BURDEN OF BRONCHIAL ASTHMA: FAMILY EXPENSES FOR CHILD'S DISEASE Prosekova, E
 1999
 2 5 p. 378-
1 p.
 article
136 TPM1: DIRECT AND INDIRECT COST OF MIGRAINE IN ITALY Arpinelli, F
 1999
 2 5 p. 376-
1 p.
 article
137 TPM2: ONE-YEAR REHOSPITALISATION RATE IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER Tavcar, R
 1999
 2 5 p. 377-
1 p.
 article
138 TPM3: THE EFFECT OF OBSERVATION DURATION ON CLAIMS-BASED RISK ADJUSTMENT SCORES Andrews, K
 1999
 2 5 p. 377-
1 p.
 article
139 TPP2: EVALUATION OF A THERAPEUTIC INTERCHANGE PROGRAM FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION Nichol, MB
 1999
 2 5 p. 373-
1 p.
 article
140 TPP1: IMPLEMENTING A MODEL OF RISK SHARING OF PHARMACEUTICAL BENEFITS IN PRIMARY CARE Gilabert, A
 1999
 2 5 p. 373-
1 p.
 article
141 TPP3: PHARMACEUTICAL CARE AND HEALTH CARE UTILIZATION Fischer, LR
 1999
 2 5 p. 373-374
2 p.
 article
142 TPP4: POTENTIAL COST SAVINGS BY PRESCRIPTION OF THE CHEAPEST DRUGS AMONG THOSE WITH EQUAL CONTENT IN PRIMARY CARE de Rey E, Alegre
 1999
 2 5 p. 374-
1 p.
 article
143 TPQ4: A EUROPEAN EQ-5D VALUE SET. MYTH OR REALITY? De Charro, F
 1999
 2 5 p. 372-
1 p.
 article
144 TPQ2: A REVIEW OF AVAILABLE HEALTH-RELATED QUALITY OF LIFE (HRQL) REFERENCE VALUES IN THE MEDICAL LITERATURE Keininger, DL
 1999
 2 5 p. 371-
1 p.
 article
145 TPQ3: EUROPEAN GUIDANCE DOCUMENT FOR THE IMPROVEMENT OF THE INTEGRATION OF HEALTH-RELATED QUALITY OF LIFE (HRQL) ASSESSMENT IN THE DRUG REGULATORY PROCESS Chassany, O
 1999
 2 5 p. 371-372
2 p.
 article
146 TPQ5: MAPI RESEARCH INSTITUTE HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROJECT Keininger, DL
 1999
 2 5 p. 372-
1 p.
 article
147 TPQ1: THE EUROPEAN REGULATORY ISSUES ON QUALITY OF LIFE ASSESSMENT (ERIQA) PROJECT Acquadro, C
 1999
 2 5 p. 371-
1 p.
 article
                             147 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands